CANCER ADVANCES
Cancer Advances is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio. Cancer Advances is a wholly owned subsidiary of Cato BioVentures. The company's lead compound, Polyclonal Antibody Stimulator (PAS), is an immunomodulator used to treat gastrointestinal cancer. Please visit their Product page for more information on what is in development.
CANCER ADVANCES
Industry:
Biotechnology
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.canceradvancesinc.com
Status:
Closed
Contact:
919-361-2286
Email Addresses:
[email protected]
Technology used in webpage:
Microsoft Exchange Online Google Maps Amazon Route 53 Network Solutions
Current Employees Featured
Official Site Inspections
http://www.canceradvancesinc.com
Unable to get host informations!!!
More informations about "Cancer Advances"
Cancer Advances
Cancer Advances Westpark Corporate Center 4364 South Alston Avenue, Suite 105 Durham, North Carolina USA 27713See details»
About - Cancer Advances
Cancer Advances, Inc., is a clinical stage bio pharmaceutical company developing therapeutics for gastrointestinal cancers and other cancers. The company is focused on impacting human …See details»
Cancer Advances - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 919-361-2286 Cancer Advances is a biotechnology company focused on impacting human health and the progression of …See details»
Cancer Advances, Inc. - Company Profile & Staff Directory
Cancer Advances was created as a wholly owned subsidiary of Cato BioVentures to acquire all the technology and intellectual property for a novel vaccine, PAS (Polyclonal Antibody …See details»
Cancer Advances, Inc. - LinkedIn
Cancer Advances, Inc. Biotechnology Research Durham, North Carolina 99 followers Cancer Advances is dedicated to pioneering new medicines and redefining possibilities for cancer …See details»
Cancer Advances Inc - Company Profile and News - Bloomberg …
Company profile page for Cancer Advances Inc including stock price, company news, executives, board members, and contact informationSee details»
Cancer Advances, Inc. Overview | SignalHire Company Profile
The company currently specializes in the Biotechnology area. Its headquarters is located at Durham, North Carolina, USA. The number of employees ranges from 1 to 25. The annual …See details»
Cancer Advances, Inc. Information - RocketReach
The NAICS codes for Cancer Advances, Inc. are [54, 541, 54171, 5417, 541713]. What is the SIC code for Cancer Advances, Inc.? The SIC codes for Cancer Advances, Inc. are [87, 873]. …See details»
Contact - Cancer Advances
Cancer Advances Westpark Corporate Center 4364 South Alston Avenue, Suite 105 Durham, North Carolina USA 27713See details»
Cancer Advances Inc. - VentureRadar
Cancer Advances, a subsidiary of Cato Bioventures, develops immunomodulator therapeutics to treat gastrointestinal cancers. ... Find out more about Cancer Advances Inc., Therapeutics, …See details»
Cancer Advances Acquires the Intellectual Property for a Suite of ...
DURHAM, N.C., Feb. 2 /PRNewswire/ -- Cancer Advances, Inc. (Cancer Advances), a Cato BioVentures portfolio company, announced today that it has completed its acquisition of all the …See details»
Cancer Advances, Inc. Announces Publication, “Vaccination
Aug 24, 2021 Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by …See details»
News & Events - Cancer Advances
DURHAM, N.C., Jan. 19, 2022 (GLOBE NEWSWIRE) — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will host a …See details»
Cancer Advances, Inc. Announces Minisymposium Presentation
Apr 8, 2021 Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by …See details»
Cancer Advances, Inc. Announces Issuance of New U.S. Patent
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, …See details»
Cancer Advances, Inc. Announces Issuance of New U.S. Patent
Feb 28, 2023 Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by …See details»
Our Science - Cancer Advances
A predominant feature of pancreatic cancer is its propensity to metastasize early and frequently (64). In fact, 90% of patients have advanced disease at the time of presentation (9).See details»
Cancer Advances, Inc. Announces Abstract at AACR - GlobeNewswire
DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces …See details»